pharmaphorum April 15, 2024
Regeneron has formed a corporate venture capital unit with $100 million a year to invest over the next five years in “biopharmaceutical, healthcare, and health technology” start-ups.
The size of the earmarked investment immediately elevates the company into the top tier of biopharma corporate VC investors, a growing group of drugmakers that invest their own funds in emerging companies for a financial return and to get closer to organisations that may provide pipeline-building opportunities.
Regeneron’s fund will be independently managed by former Regeneron executives Jay Markowitz and Michael Aberman, said the company, which said the primary interest of the new fund is in “biotechnology, devices, tools, and enabling technologies”, but will look at investments more broadly across healthcare.
Aberman was...
Today's Sponsors
Today's Sponsor